BCR-ABL Positive Acute Lymphoblastic Leukemia

Oncology·MeSH: Precursor Cell Lymphoblastic Leukemia-Lymphoma

Prevalence

30.0 / 100K

0 drugs in development·0 companies·1 clinical trial

Frequently asked questions

How many clinical trials target BCR-ABL Positive Acute Lymphoblastic Leukemia?

There are 1 clinical trial targeting BCR-ABL Positive Acute Lymphoblastic Leukemia tracked by BioSniper.

What is the prevalence of BCR-ABL Positive Acute Lymphoblastic Leukemia?

The estimated prevalence of BCR-ABL Positive Acute Lymphoblastic Leukemia is approximately 30.0 per 100,000 population.

Deep-dive into BCR-ABL Positive Acute Lymphoblastic Leukemia

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis
    BCR-ABL Positive Acute Lymphoblastic Leukemia — Drugs in Development & Clinical Trials | BioSniper